These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

611 related items for PubMed ID: 25952736

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study.
    Pfeifer A, Knigge U, Mortensen J, Oturai P, Berthelsen AK, Loft A, Binderup T, Rasmussen P, Elema D, Klausen TL, Holm S, von Benzon E, Højgaard L, Kjaer A.
    J Nucl Med; 2012 Aug; 53(8):1207-15. PubMed ID: 22782315
    [Abstract] [Full Text] [Related]

  • 4. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy.
    Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J.
    J Nucl Med; 2010 Jun; 51(6):875-82. PubMed ID: 20484441
    [Abstract] [Full Text] [Related]

  • 5. Head-to-Head Comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors.
    Johnbeck CB, Knigge U, Loft A, Berthelsen AK, Mortensen J, Oturai P, Langer SW, Elema DR, Kjaer A.
    J Nucl Med; 2017 Mar; 58(3):451-457. PubMed ID: 27660147
    [Abstract] [Full Text] [Related]

  • 6. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, Caplin ME.
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [Abstract] [Full Text] [Related]

  • 7. 64Cu-DOTATATE PET/CT for Imaging Patients with Known or Suspected Somatostatin Receptor-Positive Neuroendocrine Tumors: Results of the First U.S. Prospective, Reader-Masked Clinical Trial.
    Delpassand ES, Ranganathan D, Wagh N, Shafie A, Gaber A, Abbasi A, Kjaer A, Tworowska I, Núñez R.
    J Nucl Med; 2020 Jun; 61(6):890-896. PubMed ID: 31924723
    [Abstract] [Full Text] [Related]

  • 8. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.
    Anderson CJ, Dehdashti F, Cutler PD, Schwarz SW, Laforest R, Bass LA, Lewis JS, McCarthy DW.
    J Nucl Med; 2001 Feb; 42(2):213-21. PubMed ID: 11216519
    [Abstract] [Full Text] [Related]

  • 9. 18F-AlF-NOTA-Octreotide Outperforms 68Ga-DOTATATE/NOC PET in Neuroendocrine Tumor Patients: Results from a Prospective, Multicenter Study.
    Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Boeckxstaens L, Dekervel J, Vandamme T, Lybaert W, den Broeck BV, Laenen A, Clement PM, Geboes K, Cutsem EV, Stroobants S, Verslype C, Bormans G, Deroose CM.
    J Nucl Med; 2023 Apr; 64(4):632-638. PubMed ID: 36265911
    [Abstract] [Full Text] [Related]

  • 10. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
    Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Brandau W, Bockisch A, Boy C.
    J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
    Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Brandau W, Bockisch A, Boy C.
    Recent Results Cancer Res; 2013 Dec; 194():353-71. PubMed ID: 22918768
    [Abstract] [Full Text] [Related]

  • 13. 64Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Prospective, Head-to-Head Comparison of Imaging at 1 Hour and 3 Hours After Injection.
    Loft M, Carlsen EA, Johnbeck CB, Johannesen HH, Binderup T, Pfeifer A, Mortensen J, Oturai P, Loft A, Berthelsen AK, Langer SW, Knigge U, Kjaer A.
    J Nucl Med; 2021 Jan; 62(1):73-80. PubMed ID: 32444370
    [Abstract] [Full Text] [Related]

  • 14. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?
    Has Simsek D, Kuyumcu S, Turkmen C, Sanlı Y, Aykan F, Unal S, Adalet I.
    J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. 68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis.
    Deppen SA, Blume J, Bobbey AJ, Shah C, Graham MM, Lee P, Delbeke D, Walker RC.
    J Nucl Med; 2016 Jun; 57(6):872-8. PubMed ID: 26769864
    [Abstract] [Full Text] [Related]

  • 18. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B, Asopa R, Basu S.
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [Abstract] [Full Text] [Related]

  • 19. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
    Velikyan I, Sundin A, Sörensen J, Lubberink M, Sandström M, Garske-Román U, Lundqvist H, Granberg D, Eriksson B.
    J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
    [Abstract] [Full Text] [Related]

  • 20. The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom.
    Skoura E, Michopoulou S, Mohmaduvesh M, Panagiotidis E, Al Harbi M, Toumpanakis C, Almukhailed O, Kayani I, Syed R, Navalkissoor S, Ell PJ, Caplin ME, Bomanji J.
    J Nucl Med; 2016 Jan; 57(1):34-40. PubMed ID: 26471695
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.